| UHC Surest Medical and Drug | Category III Codes – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Cell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Genetic Testing for Hereditary Cancer – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Immune Globulin (IVIG and SCIG) – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Ophthalmologic Vascular Endothelial Growth Factor (VEGF) Inhibitors – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Provider Administered Drugs – Preferred Products – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Sodium Hyaluronate – Commercial Medical Benefit Drug Policy | 2026-07-01 |